Disclosures: Kazuma Sekiba: Nothing to Disclose, Bi-Huei Hou: Nothing to Disclose, Haoqing Chen: Nothing to Disclose, Yuanyuan Liu: Nothing to Disclose, Zhiwei Zhou: Nothing to Disclose, Ayana Crawl-Bey: Nothing to Disclose, Dylan Dodd: Nothing to Disclose 1005 LIVER SINUSOIDAL ENDOTHELIAL CELL RESPONSES TO HEPATIC CONGESTION INSTIGATE -CATENIN DEPENDENT PROLIFERATIVE RESPONSES IN PERI-CENTRAL HEPATOCYTES Papawee Sutthirat 1 Nidhi Jalan-Sakrikar 1 Maarouf Hoteit 2 Vijay Shah 1 Moira Hilscher 3 , 1 Mayo Clinic Rochester, 2 University of Pennsylvania, 3 Penn Medicine Background: Liver masses are common in patients with congestive hepatopathy (CH) and may be benign or malignant
Key published studies include: Teichman et al., 2006 (JCEM): Dose-dependent GH and IGF-1 elevation with CJC-1295 DAC in healthy adults Raun et al., 1998 (Eur J Endocrinol): Ipamorelin demonstrated selective GH release without cortisol/prolactin elevation Johansen et al., 1999: Phase I/II Ipamorelin trial showed dose-response relationship with no significant adverse effects Bowers et al., 2004: Foundational research on GHRH/GHRP synergistic GH release mechanisms Neither CJC-1295 nor Ipamorelin has completed Phase 3 clinical trials
Admin Usage Admin Usage on Peptides Clinic
If you notice a yellow or brownish hue that wasn't there before, thats a red flag for oxidation or degradation
Most of these uses come from cell and animal studies, not large human trials
